Please use this identifier to cite or link to this item:
Title: Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses
Author: Vermeulen, Roel
Saberi Hosnijeh, Fatemeh
Bodinier, Barbara
Portengen, Lützen
Liquet, Benoît
Garrido Manriquez, Javiera
Lokhorst, Henk
Bergdahl, Ingvar A.
Kyrtopoulos, Soterios
Johansson, Ann-Sofie
Georgiadis, Panagiotis
Melin, Beatrice
Palli, Domenico
Krogh, Vittorio
Panico, Salvatore
Sacerdote, Carlotta
Tumino, Rosario
Vineis, Paolo
Castagné, Raphaele
Chadeau-Hyam, Marc
EnviroGenoMarkers Consortium
Botsivali, Maria
Chatziioannou, Aristotelis
Valavanis, Ioannis
Kleinjans, Jos C. S.
Kok, Theo M. C. M. de
Keun, Hector C.
Athersuch, Toby J.
Kelly, Rachel
Lenner, Per
Hallmans, Göran
Stephanou, Euripides G.
Myridakis, Antonis
Kogevinas, Manolis
Fazzo, Lucia
Santis, Marco De
Comba, Pietro
Bendinelli, Benedetta
Kiviranta, Hannu
Rantakokko, Panu
Airaksinen, Riikka
Ruokojarvi, Paivi
Gilthorpe, Mark
Fleming, Sarah
Fleming, Thomas
Tu, Yu-Kang
Lundh, Thomas
Chien, Kuo-Liong
Chen, Wei J.
Lee, Wen-Chung
Kate Hsiao, Chuhsing
Kuo, Po-Hsiu
Hung, Hung
Liao, Shu-Fen
Keywords: Limfomes
Issue Date: 18-Apr-2018
Publisher: Wiley
Abstract: Recent prospective studies have shown that dysregulation of the immune system may precede the development of B‐cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case–control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years before diagnosis (range 2.01–15.97) in 268 incident cases of BCL (including multiple myeloma [MM]) and matched controls. Linear mixed models and partial least square analyses were used to analyze the association between levels of immune marker and the incidence of BCL and its main histological subtypes and to investigate potential biomarkers predictive of the time to diagnosis. Linear mixed model analyses identified associations linking lower levels of fibroblast growth factor‐2 (FGF‐2 p = 7.2 × 10−4) and transforming growth factor alpha (TGF‐α, p = 6.5 × 10−5) and BCL incidence. Analyses stratified by histological subtypes identified inverse associations for MM subtype including FGF‐2 (p = 7.8 × 10−7), TGF‐α (p = 4.08 × 10−5), fractalkine (p = 1.12 × 10−3), monocyte chemotactic protein‐3 (p = 1.36 × 10−4), macrophage inflammatory protein 1‐alpha (p = 4.6 × 10−4) and vascular endothelial growth factor (p = 4.23 × 10−5). Our results also provided marginal support for already reported associations between chemokines and diffuse large BCL (DLBCL) and cytokines and chronic lymphocytic leukemia (CLL). Case‐only analyses showed that Granulocyte‐macrophage colony stimulating factor levels were consistently higher closer to diagnosis, which provides further evidence of its role in tumor progression. In conclusion, our study suggests a role of growth‐factors in the incidence of MM and of chemokine and cytokine regulation in DLBCL and CLL.
Note: Reproducció del document publicat a:
It is part of: International Journal of Cancer, 2018
Related resource:
ISSN: 1097-0215
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
ijc.31536.pdf1.06 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons